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Abstract
Background:  Optimal pancreatic β-cell function is essential for the regulation of glucose
homeostasis in both humans and animals and its impairment leads to the development of diabetes.
Type 2 diabetes is a polygenic disease aggravated by environmental factors such as low physical
activity or a hypercaloric high-fat diet.
Results: Free fatty acids represent an important factor linking excess fat mass to type 2 diabetes.
Several studies have shown that chronically elevated free fatty acids have a negative effect on β-cell
function leading to elevated insulin secretion basally but with an impaired response to glucose. The
transcription factors PPARα, PPARγ and SREBP-1c respond to changing fat concentrations in
tissues, thereby coordinating the genomic response to altered metabolic conditions to promote
either fat storage or catabolism. These transcription factors have been identified in β-cells and it
appears that each may exert influence on β-cell function in health and disease.
Conclusion: The role of the PPARs and SREBP-1c as potential mediators of lipotoxicity is an
emerging area of interest.
Introduction
Fatty acids are physiologically important both structur-
ally, as components of phospholipids and glycolipids, as
well as functionally, as fuel molecules. Metabolites of fatty
acids, such as leukotrienes or prostaglandins, act as potent
mediators in many biological processes. Fatty acids pro-
vide energy [1,2], particularly in the fasted state (Figure 1),
but abnormalities in the metabolism of fatty acids can
contribute to the pathogenesis of obesity and type 2
diabetes.
Type 2 diabetes and free fatty acids
Diabetes affects 6 % of the adult population and, with a
growth rate of 6% per year, it is estimated that 200 to 300
million people worldwide will be afflicted by the end of
this decade [3]. Type 1 diabetes, which accounts for < 10
% of all cases of diabetes [4], results from autoimmune-
mediated destruction of pancreatic β-cells. The destruc-
tion may occur over months to years and can result in
complete loss of the endogenous insulin supply and
therefore results in exogenous insulin dependency.
Type 2 diabetes, which accounts for 90 to 95 % of diabetes
cases worldwide, is a heterogeneous disorder and its prev-
alence is rising. Type 2 diabetes is accompanied by
chronic insulin resistance and a progressive decline in β-
cell function [5]. Obesity is a major risk factor for the
development of type 2 diabetes [6] and is believed to con-
fer increased risk through obesity-associated insulin resist-
ance [7]. Type 2 diabetes is often associated with
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hypertriglyceridemia or increased circulating concentra-
tions of free fatty acids (FFA) [8]. Therefore, type 2 diabe-
tes can be considered a lipid disorder as well as a disease
of glucose intolerance [9].
Metabolism of fatty acids in the beta cell and 
insulin secretion
Fatty acids, not glucose, are the major endogenous energy
source for unstimulated islets [10]. This is consistent with
the observation that although islets contain little glyco-
gen, they maintain high rates of oxygen consumption in
the absence of glucose [11]. Stimulation of islets by glu-
cose diminishes fatty acid oxidation and increases total
respiration [12]. Thus, rising post-prandial plasma glu-
cose shifts the β-cells from fatty acids to glucose as an oxi-
dative fuel. However, plasma concentrations of other
nutrients such as FFA and amino acids can modulate the
process of glucose-induced insulin secretion [9]. The
plasma levels of nutrient metabolites vary with dietary
composition. Thus, feeding behavior plays an important
role in the control of islet β-cell function [13,14].
Short-term (2–6 hours) elevation of the plasma FFA con-
centration in human subjects [15] and animals [16,17]
enhances while an acute decrease inhibits glucose-stimu-
lated insulin secretion [15,18]. Following lipid infusion
or ingestion of a mixed meal, the plasma FFA concentra-
tion rises and FFA diffuse into the β-cells [19]. Within the
cytosol, fatty acids are converted to their fatty acyl CoA
derivatives (Figure 1), which in turn augment insulin
secretion via different signalling mechanisms: increased
formation of phosphatidic acid and diacylglycerol, which
directly and indirectly (through activation of protein
kinase C) enhance exocytosis of insulin stored within
secretory granules; stimulation of endoplasmic reticulum
Ca2+-adenosine triphosphatase, leading to an increase in
intracellular calcium concentration and augmentation of
insulin secretion; and closure of the K+- ATP channel with
resultant depolarization of the β-cell membrane, which
causes an increase in intracellular Ca2+ and stimulation of
exocytosis of insulin-containing granules [21]. In addi-
tion to being oxidized, glucose can be metabolized
through anaplerotic processes to increase malonyl CoA
Schematic diagram of fatty acid metabolism in the fasted state Figure 1
Schematic diagram of fatty acid metabolism in the fasted state. Counter-regulatory hormones such as catecho-
lamines act on adipocytes to increase lipolysis via hormone-sensitive lipase (HSL). Circulating FFA enter the cell and are con-
verted to acyl CoAs, catalyzed by acyl CoA synthase (ACS). Acyl CoA enter the mitochondria via carnitine palmitoyl 
transferase-I (solid square) and enter the β-oxidation cycle (stippled circle) to produce acetyl CoA that is then available for fur-
ther metabolism in the TCA cycle, leading to increased ATP and substrates for anaplerosis. In the β-cell, acyl CoA also partici-
pate as signalling molecules to promote insulin secretion (see text).
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concentrations in the β-cell. Malonyl CoA inhibits CPT-I,
thus impairing the transport of fatty acyl CoAs into the
mitochondria where they would be oxidized [20,21]. The
fact that de novo fatty acid synthesis in the β-cell is very low
[22] indicates that malonyl-CoA is used as a switch com-
pound, not as a precursor or effector molecule like long
chain fatty acyl-CoA. The cytosolic concentration of long
chain fatty acyl-CoA is controlled by feedback inhibition
of acyl-CoA synthetase, and is buffered by fatty acid and
long chain fatty acyl-CoA binding proteins [23]. The total
concentration of long chain fatty acyl-CoA in livers of fed
and fasted rats, is about 95 and 220 nmol/g dry weight,
respectively [24], however quantification of cytosolic long
chain fatty acyl-CoA in other tissues has yet to be done.
In contrast to the acute effect of elevated plasma FFA to
enhance insulin secretion, longer-term (> 48 h) exposure
results in an impaired β-cell response to glucose both in
vitro and in vivo in animals [25,26] and humans [27-31].
The inhibitory effect of chronically elevated plasma FFA is
more prominent in individuals with a genetic predisposi-
tion to develop type 2 diabetes [32], thus a reduction in
the plasma FFA concentration in type 2 diabetes improves
insulin secretion [32,33]. The term lipotoxicity describes
the deleterious effect of chronic FFA elevation on insulin
secretion from the pancreatic β-cell [34]. In the Zucker
diabetic fatty rat, chronically increased plasma FFA levels
lead initially to a physiological impairment in insulin
secretion. With time, β-cell mass is reduced by more than
50 % [26]. Within the β-cell, elevated fatty acyl CoAs
increase the formation of ceramide, a sphingolipid. Cera-
mide, in turn, augments the formation of the inducible
isoform of nitric oxide, which is toxic to the β-cell [35].
Incubation of human islets with FFA or ceramide has been
shown to cause β-cell apoptosis [36].
Transcriptional regulation of free fatty acid 
metabolism
Free fatty acid metabolism responds to varying metabolic
states partially by induction of enzymes that promote
either catabolic or anabolic processes. There are two major
classes of transcriptional regulators of enzymes involved
in fatty acid metabolism, the peroxisome proliferator-acti-
vated receptors (PPARs) and the sterol regulatory element
binding proteins (SREBPs), which both exist in several
isoforms. In general, PPARγ and SREBP-1c regulate proc-
esses involved in lipogenesis whereas lipolytic enzymes
are induced by PPARα [37].
Peroxisome proliferator-activated receptors
The PPARs form a subfamily in the nuclear receptor super-
family. PPARs, like other nuclear receptors, regulate gene
expression in response to specific ligands through their
actions as transcription factors. Peroxisomes contain
PPAR-regulated enzymes involved in fatty acid β-oxida-
tion [38]. Genetic deficiencies in peroxisome biogenesis
in the human cause an accumulation of long chain fatty
acids in cells [39]. So far, three isoforms encoded by sepa-
rate genes and designated PPARα, PPARδ and PPARγ have
been identified [40].
PPARα
PPARα was the first member of this nuclear receptor sub-
class to be described. PPARα is expressed in numerous
metabolically active tissues including liver, kidney, heart,
skeletal muscle, brown fat [41-43], and also in monocytes
[44], vascular endothelium [45] and vascular smooth
muscle cells [46].
PPARα plays an important role in the regulation of cellu-
lar uptake, activation and β-oxidation of fatty acids. The
natural, preferentially-binding ligands of PPARα are long
chain unsaturated fatty acids including arachidonic acid,
linoleic acid, and oleic acid but saturated fatty acids like
palmitic acid can also act as ligands [47]. In hepatocytes
and other tissues where it has been studied, ligand-acti-
vated PPARα binds to peroxisome proliferator response
elements (PPRE) of DNA (Figure 2) and up-regulates tran-
scription of genes involved in lipid catabolism and lipo-
protein metabolism (Table 1) [48,49]. Consequently
PPARα serves as a long chain fatty acid sensor that leads
to autoregulation of long chain fatty acid metabolism
mainly in the liver and heart and to a lesser extent in mus-
cle, thus decreasing tissue content of lipids and minimiz-
ing lipotoxicity as circulating levels fluctuate [50].
Activation of PPARα also induces hepatic proliferation,
hepatomegaly and hepatocarcinogensis in animal [51]
but not human liver [52]. Obesity is a major risk factor in
the development of type 2 diabetes and PPARα may affect
body weight through regulation of fatty acid catabolism
or expending energy [53]. PPARα ligands (such as fibrate
drugs) could therefore improve insulin sensitivity by
reducing lipid accumulation in tissues [54].
PPARδ
PPARδ was initially reported as PPARβ in Xenopus laevis
[49]. Subsequently, the receptor was cloned in the human
[55] as well as in rodents [56] and was named PPARδ.
PPARδ is expressed in a wide range of tissues and cells
with the highest levels of expression found in digestive
tract, heart, kidney, liver, adipose and brain [57]. Satu-
rated and unsaturated fatty acids are natural ligands for
PPARδ [58,59]. PPARδ is implicated in adipocyte differen-
tiation, which is induced by long-chain fatty acids [60]. In
skeletal muscle, activation of PPARδ results in induction
of proteins involved in lipid catabolism, cholesterol efflux
and respiratory coupling in skeletal muscle independent
from the effects of PPARα and PPARγ agonists [61].Nutrition & Metabolism 2005, 2:1 http://www.nutritionandmetabolism.com/content/2/1/1
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Overview of PPAR activation and effects Figure 2
Overview of PPAR activation and effects. FFA (eg. oleic acid) interact with PPAR, which dimerize with retinoid X recep-
tor (RXR) and translocate to the nucleus where the complex interacts with PPRE to activate gene transcription. The general 
effects of transcriptional activation of PPARα, PPARδ and PPARγ are shown on the right of the figure.
Table 1: Selected hepatic PPARα regulated genes with at least one functional peroxisome proliferator receptor element (PPRE) 
identified within the promoter sequence
Gene Function Species References
Acyl CoA binding protein fatty acyl-CoA ester transport rat 127
Acyl CoA oxidase peroxisomal β-oxidation rat, human 128-130
Apolipoprotein-AI and AII plasma HDL metabolism human, mouse, rat 131-134
Apolipoprotein-AV plasma triglyceride metabolism human 134
Apolipoprotein-CIII plasma HDL metabolism rat 135
Bifunctional enzyme peroxisomal β-oxidation rat 136
Carnitine palmitoyl transferase-I and -II mitochondrial β-oxidation human, mouse, rat, hamster 132, 137-139
Cytochrome P450 enzymes fatty acid and cholesterol metabolism rat, mouse, human 130, 141-145
∆6- and ∆5-desaturase desaturation of fatty acyl-CoA mouse 146
Fatty acid binding protein fatty acid binding/transport mouse 147
Fatty acid transport protein and translocase fatty acid transport mouse 148, 149
Lipoprotein lipase triglyceride clearance mouse 148, 149
Liver X receptor α cholesterol metabolism mouse 150, 151
Long-chain acyl-CoA synthetase fatty acid activation human, mouse 139, 152
Malic enzyme fatty acid synthesis mouse, rat 153, 154
Mitochondrial HMG-CoA synthase ketogenesis rat, human 152, 155
Medium-chain acyl-CoA dehydrogenase mitochondrial β-oxidation mouse 138, 139
Phospholipid transfer protein HDL metabolism human 156
Stearoyl-CoA desaturase-1 desaturation of fatty acyl CoA mouse 157
Superoxide dismutase free radical metabolism rat 158
Thiolase B mitochondrial β-oxidation rat 159
Transferrin iron transport human 160
Very long- and long-chain acyl CoA dehydrogenases mitochondrial β-oxidation mouse 139
Abbreviations: HDL, high density lipoprotein; HMG-CoA, hydroxymethylglutaryl-Coenzyme A
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PPARγ
PPARγ stimulates fatty acid storage in adipose tissue by
increasing both the storage capacity and the fatty acid flux
into adipocytes. PPARγ is expressed in many cell types,
including epithelial cells, B and T cells, macrophages,
endothelial cells, smooth muscle cells [62,63] and pre-
dominantly in adipose tissue where it is necessary for the
differentiation of adipocytes [64]. There are 2 splice vari-
ant of the isoform called PPARγ1 and γ2; the expression
distribution of PPARγ2 is more limited than that of
PPARγ1 [65].
The natural ligands of PPARγ are several unsaturated fatty
acids such as oleate, linoleate, eicosapentaenoic and ara-
chidonic acids [53]. Members of the thiazolidinedione
(TZD) family, which are known as antidiabetic com-
pounds, are synthetic ligands of PPARγ [54]. In adi-
pocytes, PPARγ increases the expression of numerous
genes involved in lipid metabolism and uptake [66,67].
Activation of PPARγ also induces adipocyte apoptosis,
which is restricted primarily to large fully differentiated
adipocytes [68]. This pro-apoptotic effect of PPARγ activa-
tion on large adipocytes, coupled with its capacity to
enhance differentiation of adipocytes de novo, favours the
formation of small adipocytes that tend to replace the
large adipocytes normally constituting white adipose tis-
sue [68].
PPARγ also negatively regulates transcription of several
genes that impair insulin action, including tumor necrosis
factor-α (TNFα) and leptin, proinflammatory cytokines
produced by adipocytes and associated with insulin resist-
ance [69-72]. Thus, the TZD drugs lower hyperglycemia,
hyperinsulinemia and hypertriglyceridemia by indirectly
enhancing the sensitivity of tissues to insulin, especially in
skeletal muscle. However, the function of PPARγ is not
restricted to adipogenesis and insulin sensitization. In
peripheral monocytes and macrophages, PPARγ agonists
inhibit the production of inflammatory cytokines [73]
and induce differentiation and apoptosis in various can-
cer cells [74,75].
Peroxisome proliferator-activated receptors 
and β-cell function
Both PPARα and PPARγ have been detected in pancreatic
β-cells [76,77]. One caveat that complicates interpretation
of some of the work described below is that PPARα and
PPARγ agonists have effects on β-cell function independ-
ent of their interaction with the transcription factors.
Thus, both fibrates and TZD can alter ATP-dependent K
channel activity and rapidly (within 10 minutes) increase
insulin secretion [78]. In addition, the generalized meta-
bolic effects of these compounds may mean that effects
observed in vitro on isolated islets may not apply to the in
vivo  situation. Therefore, the mode of delivery of the
agents (directly onto islets versus in diets) and the time
frame of study are important considerations.
In pancreatic islets, exposure to long chain fatty acids
(mixed unsaturated and saturated) induces PPARα expres-
sion [76] whereas high glucose in vitro or hyperglycemia
in vivo suppresses expression [79,80]. Artificial ligands of
PPARα such as WY14643 and clofibrate also induce
PPARα expression in rat islets [76,81,82]. Similar to hepa-
tocytes, this leads to up-regulation of enzymes favouring
lipolysis, including acyl-CoA oxidase [76,81], pyruvate
dehydrogenase-4 [82] and CPT-I [76,81].
The question arises as to the role of PPARα in the physio-
logical regulation of insulin secretion. Its induction by
long chain fatty acids and its ability to augment the insu-
lin response to low glucose [81] suggests that it may play
a role in sustaining β-cell secretory capacity during nor-
mal, cyclical periods of fasting. Thus, when glucose is low,
PPARα will be induced, favouring β-oxidation of lipids to
maintain β-cell ATP at a maintenance level. Moreover, the
ability of β-cells to oxidize lipids is a critical for resump-
tion of glucose-stimulated insulin secretion at the end of
the fasting period [17]. However, when glucose is elevated
above basal, PPARα will be reduced, allowing efficient
glucose metabolism-dependent insulin secretion while
inhibiting fatty acid oxidation. Overall, the effect of oscil-
lating PPARα activity inversely with glucose concentration
may help to maintain glucose responsiveness of the β-cell
[83]. Four-to-six-hour fasted PPARα KO mice had normal
circulating insulin [84,85] and their islets had normal glu-
cose sensitivity [84] whereas 24 hour fasted mice had a 3-
fold increase in circulating insulin [85]. The longer-term
fast would allow for greater adaptation to occur; higher
fasting insulin may reflect hepatic insulin resistance rather
than altered β-cell function.
In addition to these postulated mechanisms of PPARα
control over β-cell glucose and lipid metabolism, it has
also been proposed that amino acid metabolism might be
affected. In the liver, an increase in PPARα is associated
with a decrease in amino acid catabolism [86]. Because
glutamine metabolites are potential signaling molecules
in the β-cell [87], PPARα induction under conditions of
low glucose could impair glucose-stimulated insulin
secretion via its effects on glutamine catabolism [83]. This
hypothesis has yet to be proven.
In pathophysiological conditions involving deranged glu-
cose and lipid metabolism, altered expression of PPARα
may be important in the β-cell's lack of glucose respon-
siveness. In Zucker diabetic fatty rat islets, despite chronic
hyperlipidemia, expression of PPARα, acyl-CoA oxidase
and CPT-I mRNA is reduced [88]. It has thus been pro-
posed that glucose is the dominant regulator of PPARα inNutrition & Metabolism 2005, 2:1 http://www.nutritionandmetabolism.com/content/2/1/1
Page 6 of 12
(page number not for citation purposes)
the β-cell and that its suppression is a component of glu-
colipoxicity [89].
Glucolipotoxicity is a state in which β-cells are exposed to
elevated plasma concentrations of both glucose and FFA,
as is the case in insulin resistance. Several signalling path-
ways of the β-cell may be affected by altered PPARα
expression and the overall outcome is predicted to depend
upon whether fat or glucose has the dominant effect. In
cases where glucose is elevated relative to lipid, a chronic
reduction in PPARα would be expected to decrease the
lipid oxidizing capacity of the β-cell [88,89], eliminating
a detoxification route for fat metabolites [89]. Accumula-
tion of lipids, for example as triglyceride within the β-cell,
is associated with impaired glucose-stimulated insulin
secretion, increased ceramide formation and apoptosis
[88]. When lipid is chronically elevated relative to carbo-
hydrate, induction of PPARα presumably would cause
strong up-regulation of fat oxidizing genes but also UCP2
(see below), which would suppress glucose-stimulated
insulin secretion. The implication of these hypotheses is
that either too much or too little PPARα would impair β-
cell function. Evidence in the literature supports this con-
tention when in vitro models are employed. Notably, cul-
ture of islets or INS-1 cells with high glucose (6–20 mM)
for 48 hours strongly suppresses PPARα protein expres-
sion by 80%. As predicted, fatty acid oxidation and glu-
cose-stimulated insulin secretion are attenuated, while
islet triglyceride and lipid esterification are increased [79].
Conversely, induction of endogenous β-cell PPARα (with
clofibrate) leads to an increase in CPT-I expression and
fatty acid oxidation, resulting in blunted basal and glu-
cose-stimulated insulin secretion [90]. However, the situ-
ation is less clear when experiments are performed in vivo,
leading to the conclusion that activation of PPARα in tis-
sues other than β-cells causes indirect effects on insulin
secretion secondary to changes in peripheral insulin sen-
sitivity [83]. Thus, type 2 diabetic mice given dietary
WY14,643, a PPARα agonist, have normalized serum lip-
ids, glucose and insulin. PPARα activation also improves
glucose-stimulated insulin secretion, reduces β-cell prolif-
eration and β-cell mass compared with untreated controls
[91]. Similarly, fenofibrate-treated obese diabetes-prone
OLETF rats retain β-cell mass and have lower islet triglyc-
eride content and fatty oxidation than untreated animals
[92]. In both cases, the effects on β-cells are likely second-
ary to the observed weight loss and increase in insulin sen-
sitivity of peripheral tissues.
Chronic induction of PPARα may influence also insulin
secretion indirectly because PPRE have been found in the
promoter region of uncoupling protein-2 (UCP2) [93]. In
general, uncoupling proteins (numbered 1–3 in order of
their discovery) decrease metabolic efficiency by dissociat-
ing ATP synthesis from substrate oxidation in the mito-
chondrion by promoting translocation of protons from
the inter-membrane space, across the inner mitochondrial
membrane to the matrix [94]. Therefore, circumstances
that limit mitochondrial proton gradient formation, such
as up-regulation of UCP2 expression and activity, are pre-
dicted to limit insulin secretion. A study specifically exam-
ining the role of PPARα by use of the ligand clofibrate
demonstrated induction UCP2 in islets [90]. In liver, stim-
ulation of PPARα (or PPARδ when PPARα was absent)
caused induction of UCP2 [95]. UCP2 expression
inversely correlates with β-cell ATP and glucose-stimu-
lated insulin secretion [96-99]. The significance of these
findings is that up-regulation of UCP2 expression
suppresses glucose-stimulated insulin secretion and is
implicated as a potential contributor to lipotoxic effects
mediated by PPARα in β-cells.
PPARγ may also be an important transcriptional regulator
of both normal and abnormal metabolism in pancreatic
β-cells. In hyperglycemic, pancreatectomized rats the
expression of PPARγ mRNA is increased [80] but others
found that high fat but not high glucose up-regulates
PPARγ protein expression in vitro [100]. In adipocytes,
PPARγ alters the expression of fat metabolizing enzymes
to increase FFA uptake into storage while simultaneously
preventing the release of FFA [66,67]. However, in the β-
cell some actions of PPARγ seem to mimic those of
PPARα. Thus, one of the earliest demonstrations in islets
of direct activation of PPARγ showed that TZD caused
mobilization of triglyceride and increased FFA oxidation
in Zucker diabetic fatty rats [101], resulting in improved
insulin secretion [101,102]. This observation has been
reinforced in more recent work. Induction of PPARγ by
three different methods enhances expression of genes that
participate in fatty acid oxidation [103]. Glucose-stimu-
lated insulin secretion is enhanced by both PPARα and -γ
agonists in db/db mice [104]. Consistent with this, mice
with a partial global knockdown of PPARγ (PPARγ+/-) on
a high fat diet had blunted glucose-stimulated insulin
secretion in isolated islets that was associated with an
islet-specific accumulation of triglyceride [105] even
though insulin resistance was partially prevented [106].
The TZD increase glucokinase and GLUT2 expression and
activity via interaction with PPRE in the respective gene
promoters [107,108]. A PPARα-agonist also induced
GLUT2 expression in islets but the effect on glucokinase
was not documented [109]. Improved glucose metabo-
lism, however, has not been a consistent outcome of
PPARγ induction [103]. Nonetheless, overexpression of
PPARγ in a β-cell line is detrimental to glucose-stimulated
insulin secretion and proinsulin synthesis, with PPARγ
agonists causing a further negative effect [110]. Since
PPARγ was not detected in control cells, it is unclear
whether these results are physiologically relevant to pri-Nutrition & Metabolism 2005, 2:1 http://www.nutritionandmetabolism.com/content/2/1/1
Page 7 of 12
(page number not for citation purposes)
mary β-cell function. Interestingly, in rodent islets PPARα
is expressed at higher levels than PPARγ [76], while in
human islets the situation is reversed [111]; the functions
regulated by PPARα in rodents may be more pertinent to
PPARγ in human β-cells.
PPARγ activation also regulates some β-cell functions that
have not been ascribed to PPARα. PPARγ activation by
TZD may relieve oxidative stress in β-cells of diabetic ani-
mals [112], leading to preservation of β-cell mass
[104,112-114] and partial improvement in glucose-stim-
ulated insulin secretion from isolated islets [112]. The
potential anti-oxidative or anti-inflammatory effects of
TZD in islets of type 2 diabetes models are interesting in
light of reports that TZD reduce diabetes incidence in
non-obese diabetic (NOD) mice [115] and more general-
ized inflammatory/immune responses in a variety of tis-
sues [116]. Moreover, PPARγ appears to be a critical
determinant of β-cell expansion in response to a high fat
diet [117]. However, despite these studies showing that
PPARγ exists in β-cells and that its activation can regulate
gene expression and cell function, Rosen et al. [117]
recently showed that the TZD's antidiabetic effects are still
fully present in mice in which PPARγ has been specifically
eliminated only in β-cells. Thus, the dominant effects of
dietary TZD on insulin secretion are likely indirect, a con-
sequence of improved lipemia and glycemia.
Sterol regulatory element binding protein
The family of SREBPs governs transcriptional activation of
a large number of genes involved in regulation of lipid
metabolism, including lipogenesis, cholesterol transport
and synthesis [118]. Of interest is the high expression of
SREBP-1c in liver and adipose tissue [119], and its detec-
tion in pancreatic β-cells [120]. The primary function of
SREBP-1c is to regulate transcription of genes involved in
lipogenesis, such as acetyl-CoA carboxylase, fatty acid syn-
thase and steroyl-CoA desaturase [119] and enzymes of
glycolysis [118,119]. In the liver SREBP-1c appears to
mediate the transcription of most insulin-responsive
genes and in turn its expression, and possibly its activa-
tion, are induced by insulin [119]. Thus, SREBP-1c activity
is enhanced during periods of dietary plenty; when glu-
cose is abundant and insulin is stimulated. The outcome
of SREBP-1c activation is to promote fat-sparing, leading
to an increased synthesis of saturated and monounsatu-
rated fatty acids, triglycerides and phospholipids, as well
as enhanced glucose utilization via the glycolytic pathway
[119]. Elevation of SREBP-1c in obesity characterized by
hyperinsulinemia may therefore explain the onset of fatty
liver.
SREBP-1c appears to have a similar function in lipogene-
sis in pancreatic β-cells as in hepatocytes, but the effects
on glycolytic enzymes have received little attention. Nota-
bly, blockade of SREBP-1c expression attenuates the glu-
cose-induced increase in acetyl-CoA carboxylase activity
seen in control β-cells [121] whereas an increase in
SREBP-1c induces lipogenic enzymes, triglyceride accu-
mulation and UCP2 expression [105,122-124]. The out-
come of elevated SREBP-1c is a decrease in glucose
metabolism and glucose-stimulated insulin secretion in
all cases. Consistent with these studies utilizing molecular
manipulation of SREBP-1c expression, studies of Zucker
diabetic fatty rats demonstrate increased SREBP-1c levels
in islets [120]. SREBP-1c has also been implicated as a reg-
ulator of apoptosis in β-cells [122]; thus the loss of β-cell
mass seen in obese-diabetic models might be related to
events triggered by this transcription factor. Indeed, β-cell
apoptosis might be under control of both PPARγ and
SREBP-1c because TZD has been reported to block the
increase in SREBP-1c in diabetic fatty rats [120]; this
implies that PPARγ regulates SREBP-1c. Conversely, other
groups have evidence that SREBP-1c can up-regulate
PPARγ mRNA expression [103,123] ; thus, the relation-
ship between these two factors is not yet clear. The UCP2
promoter has a sterol response element [124] so the neg-
ative effects of SREBP-1c on insulin secretion might be
caused by its induction of UCP2. However, reducing
UCP2 expression by means of a small interfering RNA
only partially restored glucose-stimulated insulin secre-
tion in SREBP-1c-overexpressing cells. Likewise, activation
of the AMP-activated kinase partially rescued the
phenotype of the cells with SREBP-1c induction [125].
Certainly, SREBP-1c is implicated as a key contributor to
lipotoxicity, as proposed elsewhere [89,126] but further
research is required to fully understand its role in regulat-
ing insulin secretion in health and diabetes.
Conclusions
FFA exert dual effects on insulin secretion, dependent on
the duration of exposure. Acute exposure to FFA increase
glucose-stimulated insulin secretion whereas chronic
exposure attenuate glucose sensitivity of pancreatic β-
cells. The coordinated control of these processes by lipid-
sensing transcription factors and its relevance to β-cell
dysfunction in type 2 diabetes mellitus is increasingly a
subject of investigation.
PPARs (especially PPARα and PPARγ) are involved in the
long-term regulation of lipid metabolism and their activ-
ity is modulated by endogenous lipid-derived ligands.
PPAR agonists have positive effects on glucose homeosta-
sis and lipid metabolism and can reduce cardiovascular
events in obese-diabetic patients. PPARα is a fasting lipid
oxidation-glucose sparing regulator whereas PPARγ is
post-prandial lipid storing-glucose utilizing regulator. In
islets, however, both PPARα and -γ appear to have some
functions more consistent with PPARα, particularly
induction of lipid oxidizing enzymes, which is potentiallyNutrition & Metabolism 2005, 2:1 http://www.nutritionandmetabolism.com/content/2/1/1
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particularly important for maintaining basal insulin secre-
tion. Growing evidence suggests that PPARγ is a regulator
of β-cell proliferation and that PPARγ agonist-mediated
anti-oxidative effects may also contribute to anti-diabetic
activity.
SREBP-1c up-regulates lipogenic enzymes in β-cells as it
does in liver. Its chronic induction in islets of obese-dia-
betic rodents may therefore contribute to lipotoxicity by
promoting triglyceride accumulation and removing fatty-
acid derived signalling factors from the cellular pool.
SREBP-1c and PPAR functions appear to be closely linked
through cross-talk between the pathways that control
their own expression, and may function in concert to
affect not only fatty acid metabolism but also glucose
metabolism, β-cell proliferation and apoptosis.
Drugs given orally to activate PPARs can improve insulin
sensitivity of peripheral tissues and generally appear to
enhance β-cell function secondary to their insulin-sensi-
tizing effects. However, it remains possible that specific
effects on β-cells are also important contributors to the
positive metabolic effects of PPAR agonists in type 2 dia-
betes treatment.
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